NRAS Q61 neoantigen-specific T cell receptor

NRAS Q61 neoantigen-specific T cell receptor refers to a class of engineered or patient-derived T-cell receptors (TCRs) designed to target public neoantigens arising from hotspot mutations at codon 61 of the NRAS oncogene (including Q61R, Q61K, and Q61L). These mutations are highly prevalent in melanoma and other solid tumors. The TCRs are restricted to the common human leukocyte antigen allele HLA-A*01:01. When expressed in autologous T cells (TCR-T cell therapy) or reformatted into soluble bispecific T-cell engagers, these receptors enable the selective recognition and elimination of NRAS-mutant cancer cells while sparing wild-type tissues. Key research on these TCRs, including clones like TCR11L and N17.1.2, has been conducted by Memorial Sloan Kettering Cancer Center, the University of Notre Dame, and the Parker Institute for Cancer Immunotherapy.

Other names

N17.1.2N-17.1.2N 17.1.2NRAS Q61 neoantigen-specific TCRNRAS Q61-specific T-cell receptorNRAS Q61-specific TCRTCR11LTCR-11LTCR 11L